Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 12, 2014

View Archived Issues

Genetic screening to identify novel small-molecule drug targets to overcome drug resistance

Perlstein Lab raises funds for orphan disease drug discovery

Sterigenics completes acquisition of Nordion

Camp Nine changes name to Relmada Therapeutics

Development of a new human monoclonal antibody effective against NiV

ProStrakan completes acquisition of Archimedes Pharma

Data show high efficacy for CF-101 in rheumatoid arthritis and psoriasis

EDP-239 advances into combination studies with alisporivir

Sanofi licenses use of GLAAS platform to develop food allergy therapy

Biodesy enters into research collaboration with Amgen

Eisai reports topline phase III data for eribulin in non-small cell lung cancer

Genentech presents novel series of pan-Pim kinase inhibitors: candidate disclosed

Otsuka Pharmaceutical recaps milestones of first quarter of fiscal 2014

Transplant Genomics reports the development of a transplant surveillance program

Preliminary results from validation study of Oncotype DX prostate cancer test

Lundbeck profiles pipeline progress of second quarter 2014

Merck & Co. patents new BTK inhibitors

Novel anticancer marine macrolides presented by French team

Catalyst Pharmaceutical provides update on phase III Firdapse study

India CSIR discloses new agents for diabetes and dyslipidemia

miRNA biomarkers identified for oesophageal squamous cell carcinoma detection and prognosis

GlaxoSmithKline divulges novel Lp-PLA2 inhibitors

HDAC8 inhibitors patented by U.S. team

Organizations join forces to combat Ebola

Mirati's mocetinostat awarded orphan drug designation for DLBCL

The ALS Association awards 21 new research grants

TapImmune confirms new clinical trial of folate receptor alpha peptide antigens

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
Research grants support early clinical trials of ALS treatments
BioWorld Science
The ALS Association has announced the recipients of its 2025 Hoffman ALS Clinical Trial Awards. These research grants, worth up to $1 million each, support...